Skip to main content
. 2010 May 5;30(18):6387–6397. doi: 10.1523/JNEUROSCI.0764-10.2010

Figure 1.

Figure 1.

Treatment with αMT induces cortical NE depletion in NET-KO mice. Treatment with αMT (250 mg/kg) reduced cortical NE content in NET-KO mice to <5% of that observed in saline-treated WT control mice (left); n = 12 and 11 for saline-treated WT and NET-KO, respectively, and n = 6 and 5 for αMT-treated WT and NET-KO, respectively. Treatment with αMT (250 mg/kg) produced an equivalent 40–50% reduction in striatal dopamine content in WT and NET-KO mice (right); n = 12 and 10 for saline-treated WT and NET-KO, respectively, and n = 4 and 4 for αMT-treated WT and NET-KO, respectively. Treatment with αMT (250 mg/kg) produced an equivalent 70–75% reduction in cortical dopamine content in WT and NET-KO mice (right); n = 6 and 5 for saline-treated WT and NET-KO, respectively, and n = 5 and 5 for αMT-treated WT and NET-KO, respectively. Importantly, there was no difference in cortical dopamine levels observed between saline-treated NET-KO mice and WT controls; p > 0.05. Catecholamine levels were measured 2 h after treatment with saline or αMT as described previously (Wang et al., 1997); *p < 0.05, two-tailed Mann–Whitney U test, WT versus NET-KO.